REFERENCES
Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., Mc-Carthy, K. S., Ovrutskaya, I., Nowinski, C. V., & Cohen, Z. S. (2000). Secretin and autism: A two-part clinical investigation. Journal of Autism and Developmental Disorders, 30, 87-94.
Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R. C., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistics spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9-15.
Lightdale, J. R., Hayer, C., Duer, A., Lind-White, C., Siegel, B., Elliott, G. R., & Heyman, M. B. (2000). Analysis of formal language testing following an open-label trial of secretin in children with autism. Pediatric Research, 47, 29A (Abstr. 169).
Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi, M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801-1806.
Rights and permissions
About this article
Cite this article
Letter to the Editor: What to Measure in Autism Drug Trials. J Autism Dev Disord 31, 361–362 (2001). https://doi.org/10.1023/A:1017339106682
Issue Date:
DOI: https://doi.org/10.1023/A:1017339106682